Neuropathic Pain - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 485 pages report, published by Global Markets Direct

Keywords : Neuropathic Pain Therapeutic Products under Development, Key Players in Neuropathic Pain Therapeutics, Neuropathic Pain Pipeline Overview, Neuropathic Pain Pipeline, Neuropathic Pain Pipeline Assessment

Report ThumbnailJune-2017
Neuropathic Pain - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H1 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 117, 27 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 35 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Neuropathic Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Neuropathic Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H1 2017
  • Neuropathic Pain - Pipeline by AbbVie Inc, H1 2017
  • Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Aevi Genomic Medicine Inc, H1 2017
  • Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H1 2017
  • Neuropathic Pain - Pipeline by Amura Holdings Ltd, H1 2017
  • Neuropathic Pain - Pipeline by AnaBios Corp, H1 2017
  • Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Neuropathic Pain - Pipeline by AngioChem Inc, H1 2017
  • Neuropathic Pain - Pipeline by Apollo Endosurgery Inc, H1 2017
  • Neuropathic Pain - Pipeline by Aptinyx Inc, H1 2017
  • Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Neuropathic Pain - Pipeline by Astellas Pharma Inc, H1 2017
  • Neuropathic Pain - Pipeline by AstraZeneca Plc, H1 2017
  • Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H1 2017
  • Neuropathic Pain - Pipeline by BCI Pharma, H1 2017
  • Neuropathic Pain - Pipeline by BCN Peptides SA, H1 2017
  • Neuropathic Pain - Pipeline by Biogen Inc, H1 2017
  • Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H1 2017
  • Neuropathic Pain - Pipeline by Bionomics Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Cavion LLC, H1 2017
  • Neuropathic Pain - Pipeline by Celgene Corp, H1 2017
  • Neuropathic Pain - Pipeline by Cerecor Inc, H1 2017
  • Neuropathic Pain - Pipeline by Chromocell Corp, H1 2017
  • Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by CLL Pharma SA, H1 2017
  • Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H1 2017
  • Neuropathic Pain - Pipeline by ConSynance Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H1 2017
  • Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H1 2017
  • Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H1 2017
  • Neuropathic Pain - Pipeline by Eisai Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2017
  • Neuropathic Pain - Pipeline by Endece LLC, H1 2017
  • Neuropathic Pain - Pipeline by Evec Inc, H1 2017
  • Neuropathic Pain - Pipeline by Genecode AS, H1 2017
  • Neuropathic Pain - Pipeline by GL Pharm Tech Corp, H1 2017
  • Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Glialogix Inc, H1 2017
  • Neuropathic Pain - Pipeline by Grunenthal GmbH, H1 2017
  • Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Neuropathic Pain - Pipeline by Hydra Biosciences Inc, H1 2017
  • Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by InMed Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Intec Pharma ltd, H1 2017
  • Neuropathic Pain - Pipeline by Integral Molecular Inc, H1 2017
  • Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc, H1 2017
  • Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Johnson & Johnson, H1 2017
  • Neuropathic Pain - Pipeline by JT Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H1 2017
  • Neuropathic Pain - Pipeline by Kolon Life Science Inc, H1 2017
  • Neuropathic Pain - Pipeline by KPI Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Lohocla Research Corp, H1 2017
  • Neuropathic Pain - Pipeline by Mapi Pharma Ltd, H1 2017
  • Neuropathic Pain - Pipeline by MD Biosciences GmbH, H1 2017
  • Neuropathic Pain - Pipeline by Medestea Research & Production SpA, H1 2017
  • Neuropathic Pain - Pipeline by Medifron DBT Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by MEDRx Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Medy-Tox Inc, H1 2017
  • Neuropathic Pain - Pipeline by Merck & Co Inc, H1 2017
  • Neuropathic Pain - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Neuropathic Pain - Pipeline by Mundipharma International Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Nanomerics Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd, H1 2017
  • Neuropathic Pain - Pipeline by NeuroCycle Therapeutics GmbH, H1 2017
  • Neuropathic Pain - Pipeline by NeurOp Inc, H1 2017
  • Neuropathic Pain - Pipeline by Newron Pharmaceuticals SpA, H1 2017
  • Neuropathic Pain - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by NoNO Inc, H1 2017
  • Neuropathic Pain - Pipeline by Novaremed Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Novartis AG, H1 2017
  • Neuropathic Pain - Pipeline by Omeros Corp, H1 2017
  • Neuropathic Pain - Pipeline by Orion Oyj, H1 2017
  • Neuropathic Pain - Pipeline by Patagonia Pharmaceuticals LLC, H1 2017
  • Neuropathic Pain - Pipeline by PeriphaGen Inc, H1 2017
  • Neuropathic Pain - Pipeline by Pfizer Inc, H1 2017
  • Neuropathic Pain - Pipeline by Pharmaleads SA, H1 2017
  • Neuropathic Pain - Pipeline by Phosphagenics Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Prismic Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by RaQualia Pharma Inc, H1 2017
  • Neuropathic Pain - Pipeline by Re-Pharm Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Reata Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Relmada Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Revance Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Rottapharm Biotech Srl, H1 2017
  • Neuropathic Pain - Pipeline by Saniona AB, H1 2017
  • Neuropathic Pain - Pipeline by Scilex Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Shionogi & Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Pipeline by Syntrix Biosystems Inc, H1 2017
  • Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Theranexus SAS, H1 2017
  • Neuropathic Pain - Pipeline by Toray Industries Inc, H1 2017
  • Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Trevena Inc, H1 2017
  • Neuropathic Pain - Pipeline by Virobay Inc, H1 2017
  • Neuropathic Pain - Pipeline by VistaGen Therapeutics Inc, H1 2017
  • Neuropathic Pain - Pipeline by Vitality Biopharma Inc, H1 2017
  • Neuropathic Pain - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Yuhan Corp, H1 2017
  • Neuropathic Pain - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Neuropathic Pain - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Neuropathic Pain - Discontinued Products, H1 2017
  • Neuropathic Pain - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Neuropathic Pain - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Neuropathic Pain - Discontinued Products, H1 2017 (Contd..3), H1 2017
  • Neuropathic Pain - Discontinued Products, H1 2017 (Contd..4), H1 2017
  • Table of Contents
  • Table of Contents 2
  • Introduction 8
  • Neuropathic Pain - Overview 9
  • Neuropathic Pain - Therapeutics Development 10
  • Neuropathic Pain - Therapeutics Assessment 38
  • Neuropathic Pain - Companies Involved in Therapeutics Development 54
  • Neuropathic Pain - Drug Profiles 113
  • Neuropathic Pain - Dormant Projects 430
  • Neuropathic Pain - Discontinued Products 444
  • Neuropathic Pain - Product Development Milestones 449
  • Appendix 460

Please select a license type

Share

Related Products

Global Markets DirectNeuropathic Pain - Pipeline Review, H1 2017Product ThumbnailNeuropathic Pain - Pipeline Review, H1 2017, Industry ReportProduct #: 829014
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved